Brief: Resverlogix announces receipt of notice of allowance from the U.S. Patent And Trademark Office
15/03/2017 11:01
March 15 (Reuters) - Resverlogix Corp RVX.TO
* Resverlogix announces receipt of notice of allowance from
the united states patent and trademark office
* Resverlogix -receipt of notice of allowance from uspto for
patent claims covering use of apabetalone in combination with
rosuvastatin in united states
* Resverlogix corp says rosuvastatin was exclusively
marketed by astrazeneca under trade name crestor until its
patent expired in 2016
Source text for Eikon: ID:nCNWmlFXYa
Further company coverage: RVX.TO
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment